Search results - 10 results

Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries

a monthly basis, using a study period covering an eight-week follow-up period. Each month the study period was shifted forward to the following month. Country estimates were then pooled together. The study ...

Vaccine effectiveness of the second and third COVID-19 boosters in Belgium (administered during 2022 autumn campaign)

people working in the healthcare sector and those living in nursing homes in all regions of Belgium. From the 12th of September 2022 onwards, the Interministerial Conference (IMC) organised an autumn ...

Couverture vaccinale et impact épidémiologique de la campagne de vaccination COVID-19 chez les personnes présentant des maladies sous-jacentes en Belgique

affections ou plus. Cette population cible est plus âgée que la population générale, avec un âge médian de 65 ans, tandis que celui de la population ne présentant pas d’affection est de 33 ans. Une couverture ...

Characterisation of tetanus monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay.

in these products is of utmost importance for product safety and clinical effect. Immunochemical methods that measure consistency of antigen content and quality, potentially as an indicator of potency, ...

Characterisation of diphtheria monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay.

paper we report the results of the comprehensive characterisation of a panel of mAbs against diphtheria with a view to select antibodies that can be used for development of an in vitro potency immunoassay ...

Regulatory issues regarding manufacture and control of vaccine adjuvants. The EU situation.

Future Development, Meeting Management, Issue Herriot,J., Vanden Bossche,G., Lausanne, Switserland (2013) Keywords: a Activity additional ALL Aluminium an Antioxidant Antioxidants application AS assessment ...

Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.

interferon (IFN-gamma) response in spleen two- to fourfold. Further, intracellular cytokine analysis by flow cytometry also showed an increase in IFN-gamma-producing CD4 (+) T cells in ...

Cloning of the gene encoding a 22-kilodalton cell surface antigen of Mycobacterium bovis BCG and analysis of its potential for DNA vaccination against tuberculosis.

Infect. Immun. 61:2687-2693, 1993). These monoclonal antibodies were used to screen an M. bovis BCG genomic library made in phage lambdagt11. The gene encoding a 233-amino-acid (aa) protein, including ...

Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.

a set of sIPV and cIPV samples with an aim to identify a suitable reference for sIPV products. RESULTS: The study revealed differences in the reactivity of antibody reagents to cIPV and sIPV products. ...

QR code

QR code for this page URL